Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Dustin D Ruff"'
Autor:
Richard B. Lipton, Louise Lombard, Dustin D. Ruff, John H. Krege, Li Shen Loo, Andrew Buchanan, Thomas E. Melby, Dawn C. Buse
Publikováno v:
The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-15 (2020)
Abstract Background Migraine is recognized as the second leading cause of disability globally. Lasmiditan is a novel, selective serotonin 5-HT1F receptor agonist developed for acute treatment of migraine. Here we analyzed effects of lasmiditan on mig
Externí odkaz:
https://doaj.org/article/da23bbe9f2134bc4a0a5ebd3697602f8
Publikováno v:
American Journal of Men's Health, Vol 12 (2018)
Men with hypogonadism (HG) who choose testosterone replacement therapy (TRT) may have distinct characteristics that provide insight as to why they may/may not initiate therapy. The aim of the current study was to identify trends in patient characteri
Externí odkaz:
https://doaj.org/article/f11685d78c324836b2bb78f9d2aa7ffe
Publikováno v:
American Journal of Men's Health, Vol 12 (2018)
This study evaluated the effect of axillary administration of a 2% testosterone solution (Axiron ® ) in hypogonadal (HGN) men who had had a suboptimal response to treatment with a commercially available topical testosterone gel. HGN men averaging 57
Externí odkaz:
https://doaj.org/article/cb00fcd0a9e04bfbae8d727fde5aded7
Autor:
Mallikarjuna Rettiganti, Martha D. Port, Janet H. Ford, David W. Ayer, Tobias Kurth, Linda Wietecha, Amaal J. Starling, Dustin D. Ruff
Publikováno v:
Headache
Objective This post hoc study investigated the relationship between patient response in terms of migraine headache day reduction and patient‐reported outcomes of health‐related quality of life (HRQoL) and disability categories. Background Migrain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e6c9e76eefa34edc6fc472fbd37bc5b
https://doi.org/10.1111/head.14013
https://doi.org/10.1111/head.14013
Autor:
John H. Krege, Sherie A. Dowsett, Todd J. Schwedt, P A Ardayfio, Sonja M. Bragg, Erin G Doty, Cristina Tassorelli, Dustin D. Ruff
Publikováno v:
The Journal of Headache and Pain
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-8 (2021)
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-8 (2021)
Background Lasmiditan (LTN) is a selective 5-HT1F receptor agonist for the acute treatment of migraine in adults. We present detailed safety findings from the placebo-controlled, double-blind Phase 3 study, of LTN treatment across 4 attacks (CENTURIO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4895543a4e2db623beed5bfdc3c5b544
http://europepmc.org/articles/PMC8572440
http://europepmc.org/articles/PMC8572440
Autor:
Sheena K. Aurora, Yan Dong, Virginia L. Stauffer, Jakub Jedynak, David W. Dodick, Dustin D. Ruff, Eric M. Pearlman, Erin G Doty
Publikováno v:
Cephalalgia : an international journal of headache. 41(3)
Introduction Acute medication overuse is prevalent in patients with migraine. Methods In three phase 3, double-blind, randomized, placebo-controlled studies, patients with episodic migraine (EVOLVE-1 and EVOLVE-2) or chronic migraine (REGAIN) were ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c9be721a4752547174e6b5341770e26
https://pubmed.ncbi.nlm.nih.gov/33143451
https://pubmed.ncbi.nlm.nih.gov/33143451
Autor:
Antje Tockhorn-Heidenreich, Sriram Govindan, Janet H. Ford, Peter J. Goadsby, Dustin D. Ruff, Virginia L. Stauffer, Sheena K. Aurora, Gisela M Terwindt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b139fc1facd022c0fe3295c64457612d
http://hdl.handle.net/1887/3182717
http://hdl.handle.net/1887/3182717
Autor:
Li Shen Loo, Andrew S. Buchanan, Louise Lombard, Dustin D. Ruff, Dawn C. Buse, Richard B. Lipton, John H. Krege, Thomas E. Melby
Publikováno v:
The Journal of Headache and Pain
The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-15 (2020)
The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-15 (2020)
Background Migraine is recognized as the second leading cause of disability globally. Lasmiditan is a novel, selective serotonin 5-HT1F receptor agonist developed for acute treatment of migraine. Here we analyzed effects of lasmiditan on migraine dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e298e5c43010221f50ea1d6522750cae
http://europepmc.org/articles/PMC7041198
http://europepmc.org/articles/PMC7041198
Autor:
Eric M. Pearlman, Sheena K. Aurora, Erin G Doty, Sara Sacco, Dustin D. Ruff, Russell M Nichols
Publikováno v:
Headache
Objective To examine the likelihood of response with continued galcanezumab treatment in patients with episodic or chronic migraine without initial clinical improvement. Background A percentage of patients with migraine may require additional time on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cfcdd465bd1b77a43baf3209b3f9a0d
https://doi.org/10.1111/head.13443
https://doi.org/10.1111/head.13443
Publikováno v:
Headache
Objective To characterize adult patients with episodic migraine who achieved 100% response to galcanezumab treatment. Background Galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene‐related peptide (CGRP) an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c4a0af7384a8c6f3bfdcd569c811bcf
https://doi.org/10.1111/head.13427
https://doi.org/10.1111/head.13427